Avidity Biosciences Inc (RNA)
50.00
-2.55
(-4.85%)
USD |
NASDAQ |
Nov 14, 16:00
49.98
-0.02
(-0.04%)
After-Hours: 19:57
Avidity Biosciences Enterprise Value: 4.856B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 4.856B |
| November 12, 2024 | 4.174B |
| November 11, 2024 | 4.220B |
| November 08, 2024 | 4.173B |
| November 07, 2024 | 4.265B |
| November 06, 2024 | 4.234B |
| November 05, 2024 | 3.982B |
| November 04, 2024 | 3.950B |
| November 01, 2024 | 3.605B |
| October 31, 2024 | 3.651B |
| October 30, 2024 | 3.763B |
| October 29, 2024 | 3.921B |
| October 28, 2024 | 4.056B |
| October 25, 2024 | 3.984B |
| October 24, 2024 | 3.989B |
| October 23, 2024 | 4.018B |
| October 22, 2024 | 4.250B |
| October 21, 2024 | 4.172B |
| October 18, 2024 | 4.610B |
| October 17, 2024 | 4.384B |
| October 16, 2024 | 4.433B |
| October 15, 2024 | 4.171B |
| October 14, 2024 | 4.172B |
| October 11, 2024 | 4.159B |
| October 10, 2024 | 3.880B |
| Date | Value |
|---|---|
| October 09, 2024 | 4.060B |
| October 08, 2024 | 4.127B |
| October 07, 2024 | 3.848B |
| October 04, 2024 | 4.241B |
| October 03, 2024 | 4.212B |
| October 02, 2024 | 4.220B |
| October 01, 2024 | 4.383B |
| September 30, 2024 | 4.080B |
| September 27, 2024 | 3.659B |
| September 26, 2024 | 3.640B |
| September 25, 2024 | 4.083B |
| September 24, 2024 | 3.854B |
| September 23, 2024 | 3.796B |
| September 20, 2024 | 3.911B |
| September 19, 2024 | 4.048B |
| September 18, 2024 | 3.928B |
| September 17, 2024 | 3.642B |
| September 16, 2024 | 3.591B |
| September 13, 2024 | 3.586B |
| September 12, 2024 | 3.539B |
| September 11, 2024 | 3.449B |
| September 10, 2024 | 3.478B |
| September 09, 2024 | 3.475B |
| September 06, 2024 | 3.440B |
| September 05, 2024 | 3.475B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-181.71M
Minimum
Oct 27 2023
4.856B
Maximum
Nov 13 2024
887.65M
Average
619.13M
Median
Jul 17 2020
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 10.77B |
| Natera Inc | 19.38B |
| Entrada Therapeutics Inc | 297.83M |
| Alnylam Pharmaceuticals Inc | 32.35B |
| Catalyst Pharmaceuticals Inc | 2.277B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -70.79M |
| Revenue (Quarterly) | 2.045M |
| Total Expenses (Quarterly) | 84.67M |
| EPS Diluted (Quarterly) | -0.65 |
| Profit Margin (Quarterly) | -3.46K% |
| Earnings Yield | -5.90% |
| Normalized Earnings Yield | -5.900 |